Displaying drugs 7451 - 7475 of 8030 in total
Fasoracetam
Fasoracetam is under investigation in clinical trial NCT03609619 (PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without Mglur Mutations).
Investigational
Matched Description: … Fasoracetam is under investigation in clinical trial NCT03609619 (PART B: Efficacy and Safety of AEVI …
Ladarixin
Ladarixin is under investigation in clinical trial NCT04628481 (A Study of Oral Ladarixin in New-onset Type 1 Diabetes and a Low Residual Î’-Cell Function).
Investigational
Matched Description: … Ladarixin is under investigation in clinical trial NCT04628481 (A Study of Oral Ladarixin in New-onset …
Magrolimab
Magrolimab is under investigation in clinical trial NCT02953782 (Trial of Magrolimab (Hu5f9-g4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer).
Investigational
Matched Description: … Magrolimab is under investigation in clinical trial NCT02953782 (Trial of Magrolimab (Hu5f9-g4) in Combination …
Pelacarsen
Pelacarsen is under investigation in clinical trial NCT03070782 (Phase 2 Study of ISIS 681257 (Akcea-apo(a)-lrx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease).
Investigational
Matched Description: … Pelacarsen is under investigation in clinical trial NCT03070782 (Phase 2 Study of ISIS 681257 (Akcea-apo …
Viagenpumatucel-L
Viagenpumatucel-L is under investigation in clinical trial NCT02117024 (A Phase 2 Study of Viagenpumatucel-l (HS-110) in Patients With Non-small Cell Lung Cancer).
Investigational
Matched Description: … Viagenpumatucel-L is under investigation in clinical trial NCT02117024 (A Phase 2 Study of Viagenpumatucel-l …
Vafidemstat
Vafidemstat is under investigation in clinical trial NCT03867253 (Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease).
Investigational
Matched Description: … Vafidemstat is under investigation in clinical trial NCT03867253 (Testing the Safety and Preliminary Efficacy of …
TAK-611
TAK-611, formerly known as SHP611, is a recombinant human arylsulfatase A. First developed by Takeda, it is being investigated for the treatment of metachromatic leukodystrophy.
Investigational
Matched Description: … First developed by Takeda, it is being investigated for the treatment of metachromatic leukodystrophy …
KP1237
KP1237 is a antibody-redirecting molecule composed of two binding sites (a CD38 binder and a universal antibody binding terminus binder) connected by a linker chain.
Investigational
Matched Description: … KP1237 is a antibody-redirecting molecule composed of two binding sites (a CD38 binder and a universal …
Selenocysteine
A naturally occurring amino acid in both eukaryotic and prokaryotic organisms. It is found in tRNAs and in the catalytic site of some enzymes. The genes for glutathione peroxidase and formate dehydrogenase contain the TGA codon, which codes for this amino acid. [PubChem]
Experimental
Matched Description: … It is found in tRNAs and in the catalytic site of some enzymes. …
Rilapladib
Rilapladib is the third genomics-derived small molecule drug arising from the Human Genome Sciences-GlaxoSmithKline collaboration to enter clinical development. It is a lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. Lp-PLA2 is an enzyme associated with the formation of atherosclerotic plaques.
Investigational
Matched Description: … Lp-PLA2 is an enzyme associated with the formation of atherosclerotic plaques. …
Alkaline Phosphatase
Alkaline Phosphatase (AP) is an oral treatment and has a very
favorable side-effect profile. AP only acts locally in the colon to reduce the continuous inflammation of the colon by endotoxin from Gram-negative bacteria and extracellular ATP in UC patients.
Investigational
Matched Description: … AP only acts locally in the colon to reduce the continuous inflammation of the colon by endotoxin from …
Seproxetine
Seproxetine is also known as (S)-norfluoxetine. It is a selective serotonin reuptake inhibitor (SSRI). It is an active metabolite of fluoxetine. Seproxetine was being investigated by Eli Lilly as an antidepressant but development was never completed and the drug was never marketed.
Investigational
Matched Description: … It is an active metabolite of fluoxetine. …
Benactyzine
Benactyzine is an anticholinergic drug used as an antidepressant in the treatment of depression and associated anxiety.
Benactyzine is no longer widely used in medicine, although it is still a useful drug for scientific research. It does not possess any antihistamine properties.
Withdrawn
Matched Description: … Benactyzine is an anticholinergic drug used as an antidepressant in the treatment of depression and associated …
RP-A501
RP-A501 is a gene therapy product consisting of a recombinant adeno-associated virus serotype 9 (rAAV9) capsid containing the human LAMP2B transgene (AAV9:LAMP2B), which encodes lysosome-associated membrane protein 2 (LAMP-2). It is being investigated for Danon disease.
Investigational
Matched Description: … RP-A501 is a gene therapy product consisting of a recombinant adeno-associated virus serotype 9 (rAAV9 …
EGT-301
EGT-301 is a gene therapy being investigated for Hunter Syndrome. It consists of an adeno-associated viral vector serotype 9 (AAV9) containing the human Iduronate-2-sulfatase (I2S) transgene designed to restore I2S functional deficiency in patients with Hunter syndrome.
Investigational
Matched Description: … It consists of an adeno-associated viral vector serotype 9 (AAV9) containing the human Iduronate-2-sulfatase …
Coagulin-B
Coagulin-B is an adeno-associated viral vector expressing human blood-coagulation Factor IX.[A259038, A259043] It was previously investigated for the treatment of hemophilia; however, the manufacturing company discontinued the Phase I trial in 2004, halting its further development and investigation.
Investigational
Matched Description: … [A259038, A259043] It was previously investigated for the treatment of hemophilia; however, the manufacturing …
DYNE-251
DYNE-251 is a phosphorodiamidate morpholino oligomer (PMO) conjugated to a fragment antibody (Fab) that binds to the transferrin receptor 1 (TfR1). It is being investigated for the treatment of Duchenne muscular dystrophy (DMD) in patients who are amenable to exon 51 skipping.
Investigational
Matched Description: … It is being investigated for the treatment of Duchenne muscular dystrophy (DMD) in patients who are amenable …
Methyl-1-testosterone
Methyl-1-testosterone is a synthetic and orally active anabolic–androgenic steroid (AAS) which was never marketed for medical use. It is a derivative of 1-testosterone with a methyl group in the carbon 17. Methyl-1-testosterone is considered a prohibited doping substance.
Experimental
Illicit
Matched Description: … It is a derivative of 1-testosterone with a methyl group in the carbon 17. …
Oxalic Acid
A strong dicarboxylic acid occurring in many plants and vegetables. It is produced in the body by metabolism of glyoxylic acid or ascorbic acid. It is not metabolized but excreted in the urine. It is used as an analytical reagent and general reducing agent. [PubChem]
Experimental
Matched Description: … It is produced in the body by metabolism of glyoxylic acid or ascorbic acid. …
cryopreserved human liver cells
Vesta Therapeutics is a privately held company developing cell therapeutics for liver repair and regeneration. The Company's technology is centered on the isolation, expansion, and cryopreservation of liver cells (human hepatocytes) obtained from organ donor livers that are not suitable for whole organ transplantation.
Investigational
Matched Description: … The Company's technology is centered on the isolation, expansion, and cryopreservation of liver cells …
Friulimicin B
Friulimicin B is a naturally occurring antibiotic produced by a micro-organism, Actinoplanes friuliensis. It shows strong cidal activity against a number of Gram-positive pathogens which commonly cause serious infections in hospital patients and which are becoming more routinely acquired in the community.
Investigational
Matched Description: … It shows strong cidal activity against a number of Gram-positive pathogens which commonly cause serious …
Prolectin-M
Prolectin-M is a (1-6)-alpha-D-mannopyranose and acts as an antagonist of galectin. It is being investigated in the clinical trial NCT04512027 (Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support. (Prolectin-M)).
Investigational
Matched Description: … Prolectin-M is a (1-6)-alpha-D-mannopyranose[L31338] and acts as an antagonist of galectin. …
Arimoclomol
Arimoclomol is an experimental drug compound developed by CytRx Corporation, a biopharmaceutical company based in Los Angeles, California. The orally administered drug is intended to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, a neurodegenerative disease with no effective treatment.
Investigational
NBI-6024
NBI-6024 is an altered peptide ligand that is designed to cause an immune response which result in preservation of beta-cell function and endogenous insulin production.
Investigational
Matched Description: … an altered peptide ligand that is designed to cause an immune response which result in preservation of …
CPD 923
CPD 923 (N-butylgalactonorjirimycin) is an iminosugar and an analogue of ZavescaTM. It shows efficacy in vivo studies, as well as a favourable pre-clinical tolerability profile.
Investigational
Matched Description: … CPD 923 (N-butylgalactonorjirimycin) is an iminosugar and an analogue of ZavescaTM. …
Displaying drugs 7451 - 7475 of 8030 in total